8 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 8 of 8 clinical reviews.
A prescriber-level review of aromatase inhibitor drug class pharmacology, adverse-event profiles, and evidence-based management protocols for musculoskeletal, bone, cardiovascular, and CNS toxicities in breast cancer and off-label male hypogonadism settings.
A clinical-grade guide to aromatase inhibitor pharmacology, prescribing, billing codes, and prior-authorization strategies for anastrozole, letrozole, and exemestane. Written for prescribers and dispensing pharmacists.
Clinical monograph covering the aromatase inhibitor drug class: anastrozole, letrozole, and exemestane. Mechanism, dosing, trials, adverse effects, monitoring, and off-label use in men.
A full clinical reference on aromatase inhibitor drug class pharmacology, prescribing, and the complete monitoring bundle, bone density, lipids, joint symptoms, estradiol levels, and safety thresholds, written at MD/PharmD level.
A prescriber-level review of aromatase inhibitor pharmacology, dosing, and clinical management across special populations including postmenopausal women, men with hypogonadism, adolescents, and patients with hepatic or renal impairment.
A prescriber-level guide to aromatase inhibitor drug classes, dosing titration approaches, and tapering considerations for breast cancer and off-label estrogen-excess management in men, with an evidence-boundary map and a clinician-discussion checklist.
A prescriber-level guide to anastrozole, letrozole, and exemestane, covering pharmacology, clinical trial data, dosing, and agent selection criteria for breast cancer and off-label estrogen management.
Answer: estrogens counteract Arimidex by opposing its mechanism. See the full aromatase inhibitor drug interaction table with severity and management steps.